The Cambridge-based nanomedicine developer has raised capital to expand its laboratory facilities and accelerate product development for its polyNaut technology.
"We are also proud to be working with the Cystic Fibrosis Foundation on one of our key pipeline programmes, underscoring our commitment to advancing treatments for people with cystic fibrosis and other unmet clinical needs. This fundraise marks a pivotal moment in ViaNautis’s journey and we look forward to advancing the field of gene therapy, while creating substantial value for our shareholders."
The investment from BGF will support global expansion and ongoing product development for the Manchester technology firm.
"Customer experience has become a key driver across a multitude of sectors in recent years which, in turn, has sparked a wave of digitalisation in order to meet the needs and expectations of end users."
BGF contributed £3m to the oversubscribed round as the digital mental health provider scales its operations.
"Kooth is a great example of a high-quality business with a proven business model, a significant recurring revenue stream, and now international growth potential. We have a strong conviction in the management team’s ability to execute the step-change in the scale of the business following the recent US contract win, which is a clear demonstration of Kooth’s credibility and expertise in its field. This is an exceptional achievement for a UK-based business that has purpose at its core, and we’re delighted to be playing a part in its continued expansion."
